Phase Forward signs multi-year agreement with Quotient Clinical
Phase Forward announced a multi-year agreement with Quotient Clinical, which specializes in early development services for a broad range of pharmaceutical and biotech customers. :theflyonthewall.com
News For PFWD From The Last 14 Days
Check below for free stories on PFWD the last two weeks.
There are 10 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
The following stocks were the top percentage losers before the open on solid volume of at least 50,000 shares, trading at over $10. PFWD (22.6%), AIXG (4.5%), CIEN (2%), GOLD (1.6%), GLW (1.3%). :theflyonthewall.com
MOST NOTEWORTHY: Exelon (EXC), Argon ST (STST) and Leap Wireless (LEAP) were today's noteworthy downgrades: Bernstein downgraded Exelon to Market Perform from Outperform citing margin and cash flow erosion. The firm cut its target to $45 from $55. Oppenheimer downgraded Argon ST to Perform from Outperform on valuation as it believes a take-out premium is already priced into the stock. JP Morgan downgraded Leap Wireless to Underweight from Neutral. The firm believes company sale would be challenging given its weakening fundamentals and valuation and has a $10 price target on shares...OTHER DOWNGRADES: Nordstrom (JWN) was downgraded to Neutral from Buy at Goldman. Phase Forward (PFWD) was downgraded to Hold from Buy at Needham. Meritage Homes (MTH) was downgraded to Hold from Buy at Citigroup. :theflyonthewall.com
Phase Forward downgraded to Sector Perform from Outperform at PacCrest
Pacific Crest downgraded Phase Forward following the company's Q4 results to reflect earlier-than-expected saturation of the EDC market. :theflyonthewall.com
Subscribe for More Information
